Is Repligen Corp (RGEN) a risky stock?
As of July 25, 2026, Clavix grades Repligen Corp (RGEN) B for risk, a composite score of 72 out of 100 on an A+ to F scale, which puts RGEN in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 25, 2026. Clavix regrades every trading day.
RGEN price, last 3 months
RGEN's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.
The five risk dimensions behind RGEN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how RGEN scores on each, as of July 25, 2026.
What's moving RGEN's risk right now
Company-specific signals Clavix flags behind RGEN's current grade, drawn from recent news and filings as of July 25, 2026.
The investigation introduces uncertainty around the BLFS-RGEN merger, potentially complicating deal closure, prompting renegotiation of terms, or delaying the transaction timeline…
The deal expands Repligen's footprint in the bioprocessing/cell therapy solutions space, combining two complementary businesses and is expected to boost earnings and revenue upon…
The acquisition signals Repligen is making a sizeable, growth-focused bet on cell therapy bioprocessing, which could expand its addressable market and revenue base but also introd…
Recent RGEN news
The latest headlines Clavix ingested for Repligen Corp, newest first. These feed the news-sentiment dimension of RGEN's grade.
What a B grade means
On the Clavix A+ to F scale, RGEN's composite of 72 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell RGEN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.